EU Pharmaceutical Market: Problems of Competition

207
DOI: 10.20542/0131-2227-2020-64-2-53-62

N. Kondrat’eva (nkondratieva@inbox.ru),
Institute of Europe RAS, 11–3, Mokhovaya Str., Moscow, 125993, Russian Federation;
D. Khromakov (khromakov@gmail.com),
Institute of Europe RAS, 11–3, Mokhovaya Str., Moscow, 125993, Russian Federation

Abstract. The paper reviews recent developments in the enforcement of competition rules in EU pharmaceutical sector. Based on a number of antitrust cases dealt with by the European Commission, it concludes that even big and developed markets with a large number of independent actors, such as the European Union, need regulation in order to tackle anticompetitive agreements and behavior. In the first section of the text, major parameters of the industry are examined, including current production value, employment, labor productivity and trade figures. Additionally, the importance of R&D for pharmaceutical companies is emphasized especially in the light of improving global competitiveness. The second part critically discusses several most significant antitrust investigations launched by the EC over the past decade. The list of competition law infringements include price fixing, false or misleading representations, abuse of a dominant position and market or customer allocation. The method of setting fines and offering reductions is also considered. The article highlights that the goal of these investigations is not to damage the economic viability of an offender but to make antitrust violations unprofitable and thus to prevent them. The final chapter stresses that companies have the right to appeal to a court against the decision of a competition authority. The fines imposed by the European Commission are reviewed by the Court of Justice of the European Union. There have been successful appeals, but the trend is to gradually expand the definition of restriction of competition. In summary, the existing regulation framework is necessary to promote competition and protect consumer rights. The EU policy on antitrust strives to strike a balance between the interests of original pharmaceutical companies and generic producers. The former are supported by patents, government subsidies and the demand for new treatment options; for the latter, it is crucial how efficiently the authorities control attempts to preserve exclusivity by unfair market practices since the fact that patents expire is their major source of income. The European experience in this area is especially important today when the single market for medicines in the Eurasian Economic Union has entered its final stage.

Keywords: European Union, pharmaceutical market, perfect competition, competition policy, European Single Market, European Commission, Court of Justice of the European Union


REFERENCES

1. Stigler G. Sovershennaya konkurentsiya: istoricheskii rakurs [Perfect competition: historical perspective]. Vekhi ekonomicheskoi mysli. Tom 2. Teoria firmy [Milestones of economic thought. Vol. 2. Theory of firm]. St. Petersburg, School of Economics, 2000, pp. 299-328.

2. Horn K.I. Social’noe rynochnoe hozyaistvo. Vse, chto vam nuzhno znat’ o neoliberalizme [Social market economy. Everything you need to know about neoliberalism]. Moscow, “Ves’ mir”, 2017. 200 p.

3. Porter M.E. The Five Competitive Forces that Shape Strategy. Harvard Business Review, 2008, pp. 25-40.

4. Social’noe rynochnoe hozyajstvo: koncepcii, prakticheskij opyt i perspektivy primeneniya v Rossii [Social market economy: concepts, practical experience and prospects of application in Russia]. Nureev R.M., Latov Y.V., Sidorina T.U., ds. Moscow, Izd. dom HSE, 2007. 325 p.

5. Primakov E.M. Sovremennaya Rossiya i liberalizm [Contemporary Russia and Liberalism]. Rossiiskaya gazeta, no. 291(5964), 17.12.2012.

6. Kondrat’eva N.B. Konkurentsiya v ES: ekonomika, politika, pravo [Competition in the EU: economy, politics and law]. Doklady Instituta Evropy RAN, ser. 248. Moscow, 2009. 74 p.

7. Paemen D., Blondeel J. Appealing EU Cartel Decisions before the European Courts: Winning and Losing Arguments. Business Law International, 2017, vol. 18, no. 2, pp. 155-183.

8. Mamedyarov Z.A. Innovatsionnoe razvitie mirovoi farmatsevticheskoi otrasli [Innovative Development of the Global Pharmaceutical Industry]. Moscow, IMEMO, 2019. 145 p.

9. Eurostat. Annual Detailed Enterprise Statistics for Industry (NACE Rev. 2, B-E), 2019. Available at: https://ec.europa.eu/eurostat/web/products-datasets/-/SBS_NA_IND_R2 (accessed 27.06.2019).

10. Eurostat. International Trade in Medicinal and Pharmaceutical Products, 2019. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php/International_trade_in_medicinal_and_pharmaceutical_products (accessed 27.06.2019).

11. Eurostat. EU Trade since 1988 by SITC, 2019. Available at: https://data.europa.eu/euodp/en/data/dataset/PNtLrEMxMmcWouzaCbJSg (accessed 27.06.2019).

12. Verheugen G. Future Post-G10/Pharmaceutical Strategy. Available at: https://ec.europa.eu/commission/presscorner/detail/en/SPEECH_05_311 (accessed 27.06.2019).

13. Gambardella A., Orsenigo L., Pammolli F. Global Competitiveness in Pharmaceutical: A European Perspective, 2001. Avalable at: https://ec.europa.eu/docsroom/documents/2957/attachments/1/translations/en/renditions/pdf (accessed 27.06.2019).

14. Hancher L. The EU Pharmaceuticals Market: Parameters and Pathways. Health Systems Governance in Europe: The Role of EU Law and Policy. Mossialos E., Permanand G., Baeten R., Hervey T., eds. Cambridge, Cambridge University Press, 2010, pp. 635-682. Available at: http://www.euro.who.int/__data/assets/pdf_file/0004/138190/E94886_ch15.pdf (accessed 27.06.2019).

15. EFPIA. The Pharmaceutical Industry in Figures, 2018. Available at: https://efpia.eu/media/361960/efpia-pharmafigures2018_v07-hq.pdf (accessed 27.06.2019).

16. Hernandez H., Grassano N., Tubke A., Potters L., Gkotsis P. and Vezzani A. The 2018 EU Industrial R&D Investment Scoreboard. Luxembourg, Publications Office of the European Union, 2018. Available at: http://iri.jrc.ec.europa.eu/documents/10180/346814f1-e2e0-4b48-9562-0cbb2ee7c601 (accessed 27.06.2019).

17. DiMasi J.A., Grabowski H.G., Hansen R.W. Innovation in the Pharmaceutical Industry: New Estimates of R&D osts. Journal of Health Economics, 2016, vol. 47, pp. 20-33.

18. MSF Access Campaign. R&D Cost Estimates – MSF Response to Tufts CSDD Study on Cost to Develop a New Drug, 2014. Available at: https://msfaccess.org/rd-cost-estimates-msf-response-tufts-csdd-study-cost-develop-new-drug (accessed 27.06.2019).

19. European Commission. Antitrust: Commission Fines Johnson & Johnson and Novartis €16 Million for Delaying Market Entry of Generic Pain-Killer Fentanyl, 2013. Available at: https://ec.europa.eu/commission/presscorner/detail/en/IP_13_1233 (accessed 27.06.2019).

20. European Commission. Antitrust: Commission Welcomes General Court Judgments Upholding Its Lundbeck Decision in First Pharma Pay-for-delay Case, 2016. Available at: https://ec.europa.eu/commission/presscorner/detail/de/MEMO_16_2994 (accessed 27.06.2019).

21. European Commission. Mergers: Commission Approves Acquisition of Allergan Generics by Teva, Subject to Conditions, 2016. Available at: https://www.neweurope.eu/press-release/mergers-commission-approves-acquisition-of-allergan-generics-by-teva-subject-to-conditions/ (accessed 27.06.2019).

22. European Commission. Mergers: Commission Approves Acquisition of Hospira by Pfizer, Subject to Conditions European Commission, 2015. Available at: https://www.oreanda.ru/en/promyshlennost/article925728/ (accessed 27.06.2019).

23. OFT Accuses Reckitt Benckiser of Abusing Market Position. The Telegraph, 23.02.2010. Available at: https://www.telegraph.co.uk/finance/newsbysector/epic/rbdot/7297448/OFT-accuses-Reckitt-Benckiser-of-abusing-market-position.html (accessed 27.06.2019).

24. Autorite de la concurrence. The Autorite de la concurrence Fines Sanofi-Aventis a Total of €40.6 Million for Disparaging the Generic Versions of Plavix®, One of the World‘s Best-selling Medicines, 2013. Available at: http://ec.europa.eu/competition/ecn/brief/03_2013/fr_sanofi.pdf (accessed 27.06.2019).

25. CJEU. The Agreement between the Pharmaceutical Groups Roche and Novartis Designed to Reduce the Use of Avastin in Ophthalmologyand to Increase the Use of Lucentis Might Constitute a Restriction of Competition ‘by Object’, 2018. Available at: https://curia.europa.eu/jcms/upload/docs/application/pdf/2018-01/cp180006en.pdf (accessed 27.06.2019).

26. Report on Competition Enforcement in the Pharmaceutical Sector (2009–2017), 2019. Available at: http://ec.europa.eu/competition/sectors/pharmaceuticals/report2019/index.html (accessed 27.06.2019).

27. Directive (EU) 2019/1 of the European Parliament and of the Council to Empower the Competition Authorities of the Member States to be More Effective Enforcers and to Ensure the Proper Functioning of the Internal Market. Official Journal, L11, 2019.

28. Health, Demographic Change and Wellbeing. Horizon 2020: Work Programme 2018–2020, 2018. Available at: http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-health_en.pdf (accessed 27.06.2019.

29. European Commission. Fines for Breaking EU Competition Law, 2011. Available at: http://ec.europa.eu/competition/cartels/overview/factsheet_fines_en.pdf (accessed 27.06.2019).

30. CJEU. The General Court Annuls in Part the European Commission’s Decision Finding the Existence of Restrictive Agreements and an Abuse of a Dominant Position on the Market for Perindopril, a Medicine Used to Treat Hypertension and Heart Failure, 2018. Available at: https://curia.europa.eu/jcms/upload/docs/application/pdf/2018-12/cp180194en.pdf (accessed 27.06.2019).

31. European Commission. Antitrust: Commission Fines Servier and Five Generic Companies for Curbing Entry of Cheaper Versions of Cardiovascular Medicine, 2014. Available at: https://ec.europa.eu/commission/presscorner/detail/hr/IP_14_799 (accessed 27.06.2019)

32. CMA Fines Pfizer and Flynn £90 Million for Drug Price Hike to NHS, 2016. Available at: https://www.gov.uk/government/news/cma-fines-pfizer-and-flynn-90-million-for-drug-price-hike-to-nhs (accessed 27.06.2019).

33. Competition Appeal Tribunal. Judgment Summary: 1275/1/12/17, 1276/1/12/17, 2018. Available at: https://www.catribunal.org.uk/judgments/127511217-127611217-flynn-pharma-ltd-and-flynn-pharma-holdings-pfizer-inc-and-pfizer-0 (accessed 27.06.2019).

34. Pfizer Inc. and Pfizer Limited v Competition and Markets Authority. Available at: https://www.catribunal.org.uk/cases/127611217-pfizer-inc-and-pfizer-limited (accessed 27.06.2019).

35. European Commission, Case AT.39226 – Lundbeck, decision of 19 June 2013. Available at: http://ec.europa.eu/competition/antitrust/cases/dec_docs/39226/39226_8310_11.pdf (accessed 27.06.2019).

36. Siragusa M. Overview and Critical Analysis of the Main Developments in European Antitrust Practice and Case Law. Italian Antitrust Review, 2017, no. 2, pp. 9-36.


Registered in System SCIENCE INDEX

For citation:
Kondrat'eva N., Khromakov D. EU Pharmaceutical Market: Problems of Competition. World Eonomy and International Relations, 2020, vol. 64, no. 2, pp. 53-62. https://doi.org/10.20542/0131-2227-2020-64-2-53-62



Comments (0)

No comments

Add comment







Indexed

 

 

 

 

Dear authors! Please note that in the VAK List of peer-reviewed scientific journals, in which the main scientific results of dissertations for the degree of candidate and doctor of sciences should be published for the “MEMO Journal” the following specialties are recorded:
economic sciences:
5.2.5. World Economy.
5.2.1. Economic Theory
5.2.3. Regional and Branch Economics
political sciences:
5.5.4. International Relations
5.5.1. History and Theory of Politics
5.5.2. Political Institutions, Processes, Technologies

 

Current Issue
2024, vol. 68, No. 5
Topical Themes of the Issue:
  • Are There Any Ways to Break Through the Korean Nuclear Impasse?
  • Contemporary U.S. Taiwan Policy: Balancing on the Edge
  • The Gulf Monarchies’ Vision of the Global Order Transformations and the Russian Place in It
  • At Post-Soviet Space
Submit an Article
INVITATION FOR PUBLICATION
The Editorial Board invites authors to write analytical articles on the following topics:
  • changes in the processes of globalization in modern conditions
  • formation of the new world order
  • shifts in civilization at the stage of transition to a digital society

The editors are also interested in publishing synthesis articles / scientific reviews revealing the main trends in the development of certain regions of the world - Latin America, Africa, South Asia, etc.